source
- Arcus kidney cancer drug shows stronger potency than Merck's Welireg, boosting sharesArcus Biosciences reported follow‑up data from its late‑stage kidney cancer trial that suggest its experimental therapy, casdatifan, may be more potent than Merck's approved drug Welireg. Analysts…
- FDA approves Hibsago, first antisense therapy for chronic hepatitis BThe U.S. Food and Drug Administration has approved Hibsago (bepirovirsen) injection to be used alongside existing antiviral therapy for chronic hepatitis B virus infection in certain adults without…